Why the study?
Postoperative atrial fibrillation after CABG is well investigated, but little is known about its occurrence and prevention after aortic valve replacement.
Does continuous intravenous low-dose landiolol prevent postoperative atrial fibrillation in patients undergoing aortic valve replacement?
Does continuous intravenous low-dose landiolol prevent postoperative atrial fibrillation in patients undergoing aortic valve replacement?
Continuous intravenous administration of low-dose landiolol significantly reduces the incidence of postoperative atrial fibrillation following aortic valve replacement without causing hemodynamic deterioration.
Answers are grounded in this paper and cite their sources.
Supports low-dose landiolol to prevent POAF after AVR; extends beta-blocker prophylaxis evidence in valve surgery RCTs.
Background: Postoperative atrial fibrillation (POAF), a common complication of cardiac surgery, increases postoperative mortality, morbidity, and medical costs. POAF after coronary artery bypass grafting is well investigated; however, little is known about POAF after aortic valve replacement (AVR). This study aimed to investigate the efficacy of low-dose landiolol in preventing POAF after AVR. Methods: Thirty patients who underwent AVR were randomized into two groups, with or without administration of landiolol (Landiolol, N=15; Control, N=15). In Landiolol, continuous infusion of landiolol (3 µg/kg/min) was maintained for 48 h from admission to the intensive care unit. The occurrence of POAF during seven days after surgery, heart rate, blood pressure, cardiac index, and mixed venous oxygen saturation were compared between the two groups. Results: POAF occurred in one and seven patients in Landiolol (6.7%) and Control (46.7%), respectively, with significantly lower incidence in Landiolol than in Control (p=0.0352). The heart rate was significantly lower in Landiolol than in Control. No significant differences were observed in blood pressure, cardiac indices, and mixed venous hemoglobin oxygen between the two groups. Conclusions: The administration of low-dose landiolol following AVR significantly decreased the incidence of POAF without hemodynamic deterioration, suggesting that it may safely and effectively prevent POAF in patients undergoing AVR.
No takes yet. Share an insight, caveat, or question.
Oda et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: